Sun allergy — the medical term for which is photodermatosis — describes a group of skin conditions triggered by exposure to ultraviolet (UV) radiation or, in some cases, visible light. Far from being a single diagnosis, photodermatoses encompass several distinct conditions, from the common polymorphic light eruption (PLE) to rarer disorders such as solar urticaria and chronic actinic dermatitis. Understanding the correct clinical terminology matters: it shapes how these conditions are investigated, treated, and monitored. This article explains the key medical terms, types, causes, symptoms, and NHS management options for sun-related skin reactions.

What Is the Medical Term for a Sun Allergy?

The medical term is photodermatosis, an umbrella term for skin conditions triggered by UV or visible light; polymorphic light eruption (PLE) is the most common form, and 'sun allergy' is a colloquial rather than clinical term.

Have any more questions about this? Message our pharmaceutical team to get more info →

The medical term for a 'sun allergy' is photodermatosis (plural: photodermatoses) — an umbrella term used to describe a group of skin conditions triggered or worsened by exposure to ultraviolet (UV) radiation or, in some cases, visible light. The word derives from the Greek photo (light) and derma (skin), reflecting the central role of light exposure in provoking these reactions.

It is important to note that the term 'sun allergy' is a colloquial expression rather than a precise clinical diagnosis. True immunological allergies involve a specific immune response to an allergen, whereas most photodermatoses are not IgE-mediated allergic reactions. Their mechanisms vary — some are immunological, some phototoxic, and some are of uncertain origin. The most commonly encountered form in clinical practice is polymorphic light eruption (PLE), which is sometimes loosely referred to as a sun allergy by patients and in popular media.

Other related terms you may encounter include photosensitivity, which refers broadly to an abnormal skin reaction to light, and photoallergy, which describes a specific delayed (type IV) hypersensitivity reaction in which a topically applied or ingested chemical is activated by UV light to become an allergen — this is distinct from idiopathic photodermatoses such as PLE. Understanding these distinctions is clinically meaningful, as each condition has different underlying mechanisms, triggers, and management strategies. If you or a patient uses the phrase 'sun allergy', it is worth clarifying which specific condition is being described to ensure appropriate investigation and care.

Further information is available via the British Association of Dermatologists (BAD) Patient Hub and the Primary Care Dermatology Society (PCDS).

Types of Photodermatosis and How They Differ

Photodermatoses include PLE, chronic actinic dermatitis, solar urticaria, photoallergic contact dermatitis, phototoxic reactions, and actinic prurigo, each with distinct mechanisms, triggers, and management approaches.

Photodermatoses are broadly classified into several categories, each with distinct characteristics:

• Polymorphic light eruption (PLE): The most common idiopathic photodermatosis in the UK, affecting around 10% of the population (some studies report higher rates). It typically presents as an itchy rash on sun-exposed skin within hours of UV exposure, most commonly in spring and early summer. The rash can take various forms — hence 'polymorphic' — including papules, vesicles, or plaques.

• Chronic actinic dermatitis (CAD): A more severe and persistent condition, predominantly affecting older men. The skin becomes chronically inflamed and eczematous on sun-exposed areas, and patients may react to very low levels of UV and visible light.

• Solar urticaria: A rare condition in which exposure to sunlight causes hives (urticaria) within minutes. It is an immediate, immunologically mediated photosensitivity reaction; IgE may be involved in some patients, though the precise mechanism is not fully established and differs from classic delayed photoallergy.

• Photoallergic contact dermatitis: Occurs when a topical substance — such as a sunscreen ingredient, fragrance, or medication — is activated by UV light, triggering a delayed (type IV) immune response. This differs from phototoxic reactions, which are non-immunological and can occur in anyone exposed to sufficient amounts of a photosensitising agent (such as certain antibiotics or plants).

• Actinic prurigo: A rare, chronic photodermatosis with strong genetic associations (including HLA-DR4) and a predilection for certain ethnic groups, causing persistent itchy lesions on sun-exposed skin.

Distinguishing between these conditions requires careful clinical assessment, as management differs considerably across types. The BAD Patient Hub and British Photodermatology Group (BPG) provide further information on each condition.

Symptoms and How Reactions Are Diagnosed in the UK

Symptoms include redness, itching, papules, blisters, or hives on sun-exposed skin; UK diagnosis involves clinical history, phototesting, photopatch testing, and blood tests to exclude systemic causes such as lupus or porphyria.

Have any more questions about this? Message our pharmaceutical team to get more info →

The symptoms of photodermatosis vary depending on the specific condition, but common presentations include:

• Redness, itching, or burning on sun-exposed areas such as the face, neck, forearms, and chest

• Raised papules, blisters, or hives appearing within minutes to hours of sun exposure

• Eczematous or thickened skin in chronic conditions such as CAD

• Systemic symptoms (rare) such as headache or nausea in severe phototoxic reactions

In the UK, diagnosis typically begins with a thorough history taken by a GP, including the timing of reactions relative to sun exposure, any relevant medications, and personal or family history of skin conditions. The GP may refer the patient to a consultant dermatologist for specialist assessment.

Key diagnostic investigations used in UK dermatology departments include:

• Phototesting: Controlled exposure of small skin areas to measured doses of UV radiation to identify the wavelengths responsible for triggering a reaction, carried out in accordance with BPG phototesting guidance

• Photopatch testing: Used to identify photoallergic contact dermatitis by applying suspected substances to the skin and then exposing the area to UV light, following BPG photopatch testing protocols

• Blood tests: To exclude systemic causes of photosensitivity, such as lupus erythematosus or porphyria, which can present with similar symptoms. Typical investigations may include antinuclear antibody (ANA), extractable nuclear antigen (ENA), complement levels, and porphyrin studies, where clinically indicated

The BAD and the British Photodermatology Group (BPG) provide the primary UK guidance supporting a structured approach to investigation, ensuring that rarer but serious underlying causes are not overlooked. Accurate diagnosis is essential before commencing treatment, as management strategies differ significantly between conditions.

Causes and Risk Factors for Sun Sensitivity

Causes range from an abnormal immune response to UV-modified skin proteins in PLE to chemical photosensitisation by medications or plants; fair skin, female sex, and certain drugs are key risk factors.

The causes of photodermatosis are varied and depend on the specific condition. In idiopathic forms such as PLE, the exact mechanism is not fully understood, but it is thought to involve an abnormal immune response to UV-modified skin proteins, whereby the immune system fails to develop the usual tolerance to sunlight. This may explain why PLE often improves with repeated sun exposure over a season — a phenomenon known as 'hardening'.

In photoallergic and phototoxic reactions, the cause is more clearly defined. Phototoxic reactions occur when a chemical — whether ingested or applied topically — absorbs UV radiation and releases energy that damages skin cells. Common culprits include:

• Medications: Tetracycline antibiotics (including doxycycline), fluoroquinolones, thiazide diuretics, amiodarone, NSAIDs (including topical ketoprofen and piroxicam), and certain antifungals — refer to individual Summary of Product Characteristics (SmPC) via the MHRA/EMC and the BNF for product-specific photosensitivity information

• Topical agents: Certain sunscreen chemicals (e.g., older formulations containing PABA), fragrances, and coal tar preparations

• Plants: Contact with plants such as giant hogweed, parsnip, or lime followed by sun exposure can cause severe phototoxic reactions (phytophotodermatitis)

Risk factors for developing photodermatosis include:

• Fair skin (Fitzpatrick skin types I–II): Less melanin provides reduced natural UV protection

• Female sex: PLE is more common in women

• Genetic associations: Particularly relevant in actinic prurigo (e.g., HLA-DR4)

• Certain medications or supplements: As listed above

• Underlying systemic conditions: Including lupus erythematosus, porphyria, and — rarely in the UK — pellagra (niacin deficiency)

Understanding the cause is critical, as removing a triggering medication or substance can resolve the condition entirely in phototoxic and photoallergic cases. Patients should always consult their GP or pharmacist before stopping any prescribed medication.

Treatment and Management Options Available on the NHS

NHS management centres on broad-spectrum photoprotection, with narrowband UVB phototherapy for recurrent PLE, topical corticosteroids for flares, and hydroxychloroquine or immunosuppressants for severe cases under specialist supervision.

Management of photodermatosis on the NHS is guided by the specific diagnosis, severity, and impact on quality of life. For most patients with mild-to-moderate PLE, photoprotection measures form the cornerstone of management:

• Broad-spectrum sunscreen with an SPF of 30 or higher and a UVA rating of 4 or 5 stars (UK rating system), applied generously and reapplied regularly to exposed skin

• Protective clothing, including wide-brimmed hats and long sleeves

• Avoiding peak UV hours (typically 11am–3pm in the UK)

Patients who practise strict, year-round photoprotection should be advised to take a vitamin D supplement of 10 micrograms (400 IU) daily, in line with UK recommendations, as reduced sun exposure can impair cutaneous vitamin D synthesis.

For patients with more troublesome or recurrent PLE, desensitisation phototherapy — also known as hardening — may be offered by NHS dermatology departments. Narrowband UVB (NB-UVB) is generally the preferred first-line phototherapy option, as it carries a more favourable long-term safety profile. PUVA (psoralen plus UVA) may be used selectively in certain cases but is generally reserved due to its cumulative risk of skin cancer with repeated courses; this should be discussed with patients as part of informed consent, in line with BAD and BPG phototherapy guidance.

Pharmacological options include:

• Topical corticosteroids: Used short-term to manage acute flares and reduce inflammation

• Non-sedating antihistamines: Helpful in solar urticaria to reduce urticarial symptoms; higher doses may be considered under specialist guidance, with referral for specialist therapies (such as omalizumab) in refractory cases

• Hydroxychloroquine: An antimalarial sometimes prescribed for severe or refractory PLE and actinic prurigo. The dose should not exceed 5 mg/kg actual body weight per day. Baseline and annual retinal monitoring is required in line with the MHRA Drug Safety Update and Royal College of Ophthalmologists (RCOphth) recommendations; prescribers and patients should refer to current guidance before initiating treatment

• Systemic immunosuppressants (e.g., azathioprine): Reserved for severe CAD under specialist supervision

For phototoxic or photoallergic reactions, identifying and withdrawing the causative agent is the primary intervention. Suspected drug-induced photosensitivity reactions should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Patients should always consult their GP or pharmacist before stopping prescribed medications.

When to Seek Medical Advice and What to Expect

Seek medical advice for any new or worsening post-sun rash, severe blistering, symptoms on unexposed skin, suspected drug-induced photosensitivity, or significant impact on daily life; GPs can initiate investigation and refer to NHS dermatology.

Many people experience mild sun sensitivity and manage it effectively with over-the-counter photoprotection. However, there are circumstances in which it is important to seek medical advice promptly:

• A new or worsening rash that appears consistently after sun exposure and does not resolve within a few days

• Severe blistering or swelling following sun exposure, particularly if accompanied by systemic symptoms such as fever or difficulty breathing

• Symptoms occurring in covered or unexposed skin, which may suggest a systemic cause rather than a simple photodermatosis

• Suspected drug-induced photosensitivity, especially if a new medication has recently been started

• Significant impact on daily life or mental wellbeing, as photodermatosis can affect work, social activities, and quality of life

When you consult your GP, they will typically take a detailed history and may carry out initial blood tests to exclude systemic conditions such as lupus or porphyria. If a specialist opinion is needed, a referral to an NHS dermatologist will be made. Waiting times vary by region, but urgent referrals are available where a serious underlying condition is suspected.

Most idiopathic photodermatoses, including PLE, are not associated with an increased risk of skin cancer. However, patients with chronic photosensitivity should remain vigilant about any new or changing skin lesions and attend routine skin checks as advised by their clinician. The NHS recommends that all patients with photosensitivity continue to practise sun-safe behaviours year-round — not only during summer months — as UV radiation is present even on overcast days in the UK.

Patients who need to avoid sun exposure strictly should discuss vitamin D supplementation (10 micrograms/400 IU daily) with their GP or pharmacist to maintain adequate levels.

With the right diagnosis and management plan, most people with photodermatosis can significantly reduce their symptoms and maintain a good quality of life.

Key UK resources: BAD Patient Hub (bad.org.uk/patient-information); British Photodermatology Group (BPG); PCDS (pcds.org.uk); NHS (nhs.uk/conditions/sunscreen-and-sun-safety); MHRA Yellow Card (yellowcard.mhra.gov.uk).

Frequently Asked Questions